ClinicalTrials.gg
TerminatedNCT06566092Updated Oct 16, 2026

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

A Phase 1 interventional study of LN-145/LN-144 in Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma and Melanoma, sponsored by Iovance Biotherapeutics, Inc.. Terminated at 5 sites in United States. Open to participants aged 6 Months to 21 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Iovance Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2024, registered Jul 2024).
Updated Oct 16, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
6 Months to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 243 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
729th of 800
5 · median 35
Started
2024
with 26 others
Phase 1
281 of 958
36 open now
Registered
882nd of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 729th largest by enrollment of the 800 interventional ones that give a count, is one of 27 that started in 2024, is one of 281 in phase 1, and was the 882nd registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 301 Sarcoma studies recruiting now, 191 (63%) set no upper age limit and 83 (28%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 6 Months to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer. The study will enroll children, teenagers, and young adults with solid tumors that have returned or are not responding to treatment for whom no effective standard-of-care treatment options exist.

Study details include:

  • The study will last up to 2 years after the TIL infusion (Day 0) for each person.
  • The treatment will last up to 10 days for each person.
  • Study visits will be every 2 weeks until Day 42, every 6 weeks until Month 6, and every 3 months until Year 2.
03

Conditions studied

  • Soft Tissue Sarcoma
  • Primary Central Nervous System Carcinoma
  • Melanoma
  • Rhabdomyosarcoma
  • Ewing Sarcoma

Keywords

  • Tumor Infiltrating Lymphocytes
  • TIL
  • Pediatric
  • Soft Tissue Sarcoma
  • Primary Nervous System Carcinoma
  • PCNS
  • Rhabdomyosarcoma
  • RMS
  • Ewing Sarcoma
  • EWS
04

Who can participate

Ages eligible
6 Months to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is ≥ 8 kg and ≤ 21 years of age at the time of and assent.
  2. or cytologically confirmed recurrent or solid tumor (Rhabdomyosarcoma, Ewing sarcoma, primary CNS , melanoma) after standard therapy which has failed all available curative therapy.
  3. Acceptable performance status and an estimated of > 6 months.
  4. At least one resectable lesion (solitary or aggregate lesions) for TIL generation.
  5. Following tumor resection for TIL generation, the participant will have at least one remaining for response assessment.
  6. Preplanned surgical procedure(s) will take place at least 14 days (for major operative procedures) prior to the tumor resection.
  7. All prior anticancer treatment-related AEs should be recovered, exceptions are peripheral neuropathy, alopecia, vitiligo, or medically controlled endocrine dysfunction.
  8. Agreement to abide by the protocol indicated use, including refraining from donating sperm or eggs (ova, oocytes), as appropriate for the age and sexual activity of pediatric, adolescent, and young adult participants and as required by local regulations.
  9. Signed informed consent and assent when applicable.
  10. Written authorization for use and disclosure of protected health information.
  11. Ability to adhere to the study visit schedule and other protocol requirements.
  12. Acceptable hematologic parameters.
  13. Adequate organ function.
  14. Modified Ross criteria class 1 and an LVFS > 25% or an ≥ 50%.
  15. Adequate pulmonary function.
  16. Participant and/or the legal guardian who provided consent is willing for the participant to receive optimal supportive care.
  17. A legal guardian or primary caregiver must be available to help the study-site personnel ensure follow-up and accompany the participant to the study site on each assessment day according to the SoA.

Exclusion criteria

Exclusion Criteria:

  1. Participant with a non-CNS tumor has symptomatic untreated and/or carcinomatous meningitis.
  2. Participant has an active or uncontrolled intercurrent illness(es) that would pose increased risks for study participation.
  3. Participants are not eligible if they experience uncontrolled seizures.
  4. Participants with history of intracranial hemorrhage/spinal cord hemorrhage.
  5. Participant has active uveitis that requires active treatment.
  6. Participant has significant psychiatric disease or substance abuse in the investigator's opinion that would prevent adequate .
  7. Participant has any form of primary or acquired immunodeficiency.
  8. History of , asthma, interstitial lung disease, or other chronic lung disease.
  9. History of reaction to any components of the study intervention.
  10. Any other condition that in the investigator's judgment would significantly increase the risks of participation.
  11. Any complication or delayed healing from an excisional procedure that in the investigator's opinion would increase the risks of participation.
  12. Another primary within the previous 3 years.
  13. History of allogeneic cell or organ transplant.
  14. Requiring systemic therapy higher than the physiologic replacement dose.
  15. Received or will receive a live or attenuated vaccination within 28 days prior to the start of the NMA-LD.
  16. Any active viral, bacterial, or fungal infection requiring ongoing systemic treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Rhabdomyosarcoma (RMS)

    Biological: LN-145/LN-144

  • Experimental
    Ewing Sarcoma (EWS)

    Biological: LN-145/LN-144

  • Experimental
    Primary Central Nervous System Tumor

    Biological: LN-145/LN-144

  • Experimental
    Melanoma

    Biological: LN-145/LN-144

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence rate of Treatment-Emergent Adverse Events

    To evaluate the safety and tolerability of the TIL regimen that occurs from the start of TIL infusion and up to 30 days after TIL infusion per CTCAE.

    Time frame: Up to 24 months

Secondary outcomes

  1. Objective Response Rate

    To evaluate the proportion of participants who have confirmed complete response (CR) or partial response (PR) per RECIST v1.1 or RAPNO.

    Time frame: Up to 24 months

  2. Duration of Response

    To measure the time that criteria are met for complete response (CR) or partial response (PR) per RECIST v1.1 or RAPNO.

    Time frame: Up to 24 months

  3. Disease Control Rate

    To measure by the percentage of participants with best overall confirmed response of complete response (CR) or partial response (PR) at any time or stable disease (SD) for at least 4 weeks per RECIST v1.1 or RAPNO.

    Time frame: Up to 24 months

  4. Progression-Free Survival

    To evaluate the time from the date of the TIL infusion until disease progression per RECIST v1.1 or RAPNO.

    Time frame: Up to 24 months

  5. Overall Survival

    To measure the time from the date of TIL infusion to death due to any cause.

    Time frame: Up to 24 months

07

Study locations

5 sites
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
  • Johns Hopkins All Children's Hospital
    St. Petersburg, Florida 33701, United States
  • Rutgers Cancer Institute
    New Brunswick, New Jersey 08901, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14203, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2024 to primary completion in Jun 2026, 26 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jul 2026 → Jun 2026 and completion Jul 2028 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Aug 22, 2024
StartActual
Mar 28, 2024
Primary completionActual
Jun 19, 2026was Jul 2026
CompletionActual
Jun 19, 2026was Jul 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.
changed Oct 16, 2026
Primary completion
Jul 2026→Jun 19, 2026 (actual)
Oct 16, 2026
Study completion
Jul 2028→Jun 19, 2026 (actual)
Oct 16, 2026
Enrollment
40 (estimated)→5 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Terminated
    Why stopped After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.
    Primary completion Jul 2026→Jun 19, 2026 (now actual)
    Study completion Jul 2028→Jun 19, 2026 (now actual)
    Enrollment 40 (estimated)→5 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06566092
Lead sponsor
Iovance Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Mar 28, 2024
Primary completion
Jun 19, 2026
Completion
Jun 19, 2026
Last update
Oct 16, 2026

Study contacts

Iovance Biotherapeutics Study Team
study director · Iovance Biotherapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145

Start the discussion